Selective IL-2 responsiveness of regulatory T Cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes

A. Yu; I. Snowhite; F. Vendrame; M. Rosenzwajg; D. Klatzman; A. Pugliese; T. R. Malek

doi:10.1089/dia.2016.2507

Selective IL-2 responsiveness of regulatory T Cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes

A. Yu, I. Snowhite, F. Vendrame, M. Rosenzwajg, D. Klatzman, A. Pugliese, T. R. Malek

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	S73
Journal	Diabetes Technology and Therapeutics
Volume	18
DOIs	https://doi.org/10.1089/dia.2016.2507
State	Published - Feb 2016

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology
Medical Laboratory Technology

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access to Document

10.1089/dia.2016.2507

Cite this

Selective IL-2 responsiveness of regulatory T Cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. / Yu, A.; Snowhite, I.; Vendrame, F.; Rosenzwajg, M.; Klatzman, D.; Pugliese, A.; Malek, T. R.

In: Diabetes Technology and Therapeutics, Vol. 18, 02.2016, p. S73.

Research output: Contribution to journal › Comment/debate › peer-review

@article{c1bfcf913bb946d6a0160431b5e6da05,

title = "Selective IL-2 responsiveness of regulatory T Cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes",

author = "A. Yu and I. Snowhite and F. Vendrame and M. Rosenzwajg and D. Klatzman and A. Pugliese and Malek, {T. R.}",

year = "2016",

month = feb,

doi = "10.1089/dia.2016.2507",

language = "English (US)",

volume = "18",

pages = "S73",

journal = "Diabetes Technology and Therapeutics",

issn = "1520-9156",

publisher = "Mary Ann Liebert Inc.",

}

TY - JOUR

T1 - Selective IL-2 responsiveness of regulatory T Cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes

AU - Yu, A.

AU - Snowhite, I.

AU - Vendrame, F.

AU - Rosenzwajg, M.

AU - Klatzman, D.

AU - Pugliese, A.

AU - Malek, T. R.

PY - 2016/2

Y1 - 2016/2

UR - http://www.scopus.com/inward/record.url?scp=84957628953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957628953&partnerID=8YFLogxK

U2 - 10.1089/dia.2016.2507

DO - 10.1089/dia.2016.2507

M3 - Comment/debate

AN - SCOPUS:84957628953

VL - 18

SP - S73

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

SN - 1520-9156

ER -

Selective IL-2 responsiveness of regulatory T Cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this